---
title: Effects of tofersen treatment in patients with <em>SOD1</em>-ALS in a "real-world"
  setting - a 12-month multicenter cohort study from the German early access program
date: '2024-02-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38384337/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240222170805&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: In April 2023, the antisense oligonucleotide tofersen was
  approved by the U.S. Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic
  lateral sclerosis (ALS), after a decrease of neurofilament light chain (NfL) levels
  had been ...'
disable_comments: true
---
BACKGROUND: In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral sclerosis (ALS), after a decrease of neurofilament light chain (NfL) levels had been ...